Introduction: Exenatide is primarily eliminated through the kidneys. Safety/efficacy of exenatide once weekly (EQW) were characterized in patients (pts) with CKD stage 2 and 3 (mild and moderate renal impairment).

Methods: Pts treated with EQW or placebo/non-GLP-1RA comparator drug (sitagliptin, metformin, pioglitazone, dapagliflozin, insulin) from 8 phase 3 double-blind or open-label 26/28-week studies were pooled and stratified by CKD stage. Studies were performed on a broad range of background drugs.

Results: Pts with baseline CKD2 (N=772) or CKD3 (N=182) on EQW differed in some baseline characteristics: age <65 y (79% vs. 56%), mean BMI (31.6 vs. 28.3 kg/m2), and T2D duration (7.6 vs. 9.7 y), while BP (131/79 vs. 133/77) and HbA1c (8.5% vs. 8.3%) were similar. CKD3 EQW pts were mostly Asian (61% vs. 20% CKD2) as 59% of these were from a Japanese study. Efficacy was similar in CKD2 vs. CKD3 pts (Figure).

Rates of any AE were slightly higher in CKD3 vs. CKD2 pts (EQW: 81% vs. 72%; comparators: 74% vs. 68%) and for AEs leading to study or treatment discontinuation (EQW: 8% vs. 5%; comparators: 4% vs. 2%) but similar for SAEs (EQW: 3% vs. 3%; comparators: 6% vs. 5%). One pt in each arm had a SAE of acute kidney injury: EQW in CKD3 and comparator in CKD2 group.

Conclusion: Pooled results of 8 studies show EQW is well tolerated and efficacious in pts with CKD2 and 3. Changes in HbA1c, body weight, and SBP were similar between the 2 CKD groups.


C. Guja: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Lilly Diabetes, Novo Nordisk A/S, Sanofi. Speaker's Bureau; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Lilly Diabetes, Merck Sharp & Dohme Corp., Novo Nordisk A/S, Sanofi. J.P. Frias: Advisory Panel; Self; Becton, Dickinson and Company, Eli Lilly and Company, Gilead Sciences, Inc., Sanofi. Consultant; Self; Echosens, Genentech, Inc., Johnson & Johnson Diabetes Institute, Novo Nordisk Inc., Zafgen, Inc. Research Support; Self; AbbVie Inc., Akcea Therapeutics, Allergan, Amgen Inc., AstraZeneca, Bayer US, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Cirius Therapeutics, Elcelyx Therapeutics, Inc., Eli Lilly and Company, Enanta Pharmaceuticals, Inc., GENFIT, Intarcia Therapeutics, Inc., Intercept Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., NGM Biopharmaceuticals, Novartis Pharmaceuticals Corporation, Novo Nordisk A/S, Oramed Pharmaceuticals, Pfizer Inc., Sanofi, TaiwanJ Pharmaceuticals Co., Ltd., Theracos, Inc. Speaker's Bureau; Self; Merck & Co., Inc., Sanofi. L.J. Suchower: Stock/Shareholder; Self; AstraZeneca, Express Scripts, Merck & Co., Inc. Other Relationship; Self; AstraZeneca. E. Hardy: Employee; Self; AstraZeneca. Stock/Shareholder; Self; AstraZeneca. J. Holden: Employee; Self; AstraZeneca. Stock/Shareholder; Self; AstraZeneca. C. Sjöström: Employee; Self; AstraZeneca. Stock/Shareholder; Self; AstraZeneca. S. Jabbour: Consultant; Self; AstraZeneca, Janssen Pharmaceuticals, Inc.



Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at